New Pre-validated Fluorinated Fragment Library Boosts Drug Screening Efficiency
Researchers engaged in drug discovery can now benefit from a new library of fluorinated compounds with superior drug-like characteristics designed to maximize the efficiency of fluorine Nuclear Magnetic Resonance (NMR) and X-ray crystallography screening, saving both time and cost in the process.
The new Maybridge Fluorine Labeled Fragment Library is a diverse fragment library of 480 fluorinated compounds that has been developed in collaboration with Argenta, a Charles River Company, the University of Kent and the United Kingdom’s Biotechnology and Biological Sciences Research Council.
Approximately 20% of known drug compounds contain a fluorine atom. As such, fluorine NMR is a fast-growing technique used in fragment screening, an important method for rapid identification of new lead molecules in drug discovery due to the higher hit probability and fewer fragments needing to be screened.
“Fragment-based lead discovery programmes are often arduous and expensive, with many hits failing further down the line because of less-than-optimal physico-chemical properties,” said Simon Pearce, product manager, global chemicals, Thermo Fisher Scientific. “Our new library of drug-like fluorinated fragments has been carefully designed and curated to reduce these problems, giving researchers a head start in drug discovery programs.”
This Maybridge Library was derived from more than 5000 fluorinated candidates and was optimized through a stringent biophysical selection process to increase the probability of hit generation. Each compound has been validated using fluorine and standard NMR, solubility testing, X-ray crystallography and Surface Plasmon Resonance (SPR) techniques to provide the highest quality. Product highlights include
• Design maximizes structural diversity, pharmacophore content and Rule of Three (Ro3) compliance, while eliminating compounds with reactive functional groups
• Compound solubility has been confirmed (aqueous PBS >=1 mM / DMSO >= 100 mM) and screened by SPR against proteins from two different gene families
• Comprehensive pre-qualification designed to give researchers a high hit probability and diminished risk of future attrition, while generating excellent data from screening programs in a shorter time-frame
·• Quality filters, including adherence to “Rule of Three,” assuring that every compound possesses key physio-chemical properties frequently found in orally active drugs.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance